Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $9.8100 (-5.67%) ($9.7300 - $10.6300) on Tue. Feb. 25, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.33% (three month average) | RSI | 54 | Latest Price | $9.8100(-5.67%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -1.9% a day on average for past five trading days. | Weekly Trend | FOLD advances 0.4% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(60%) IWO(56%) XBI(55%) IWM(53%) IWC(51%) | Factors Impacting FOLD price | FOLD will decline at least -1.665% in a week (0% probabilities). VIXM(-33%) VXX(-19%) TLT(-13%) IGOV(-6%) UNG(-1%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.665% (StdDev 3.33%) | Hourly BBV | 0 () | Intraday Trend | -6.1% | | | |
|
Resistance Level | $10.24 | 5 Day Moving Average | $10.53(-6.84%) | 10 Day Moving Average | $10.71(-8.4%) | 20 Day Moving Average | $10.24(-4.2%) | To recent high | -12.1% | To recent low | 11% | Market Cap | $2.533b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |